Method to inhibit cell growth using oligonucleotides

Details Method to inhibit cell growth using oligonucleotides Method to inhibit cell growth using oligonucleotides

2006-04-25

2006-04-25

Schultz, J. D. (Department: 1635)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

Method of regulating cell metabolism or physiology

C435S006120, C435S325000, C435S377000, C514S04400A, C536S023100, C536S024500

Reexamination Certificate

active

07033829

ABSTRACT:
Described are methods for treating hyperproliferative disorders, including cancers, by administering to the affected mammal (e.g., human) an effective amount of a composition comprising pTT or a composition comprising one or more oligonucleotides which share at least 50% nucleotide sequence identity with the human telomere overhang repeat. Methods of treatment or prevention of hyperproliferative diseases or pre-cancerous conditions affecting epithelial cells, such as psoriasis, atopic dermatitis, or hyperproliferative or UV-responsive dermatoses, hyperproliferative diseases of other epithelia and methods for reducing photoaging, or oxidative stress or for prophylaxis against or reduction in the likelihood of the development of skin cancer, are also disclosed.

REFERENCES:
patent: 3937809 (1976-02-01), Jacobi
patent: 4419343 (1983-12-01), Pauly
patent: 4508703 (1985-04-01), Redziniak et al.
patent: 4621023 (1986-11-01), Redziniak et al.
patent: 5077211 (1991-12-01), Yarosh
patent: 5455029 (1995-10-01), Hartman et al.
patent: 5470577 (1995-11-01), Gilchrest et al.
patent: 5489508 (1996-02-01), West et al.
patent: 5532001 (1996-07-01), Gilchrest et al.
patent: 5580547 (1996-12-01), Gilchrest et al.
patent: 5599672 (1997-02-01), Liang et al.
patent: 5643556 (1997-07-01), Gilchrest et al.
patent: 5643890 (1997-07-01), Iversen et al.
patent: 5645986 (1997-07-01), West et al.
patent: 5837857 (1998-11-01), Villaponteau et al.
patent: 5858987 (1999-01-01), Beer-Romero et al.
patent: 5879713 (1999-03-01), Roth et al.
patent: 6007989 (1999-12-01), West et al.
patent: 6015710 (2000-01-01), Shay et al.
patent: 6046307 (2000-04-01), Shay et al.
patent: 6147056 (2000-11-01), Gilchrest et al.
patent: 6194206 (2001-02-01), West et al.
patent: 6320039 (2001-11-01), Villeponteau et al.
patent: 6440650 (2002-08-01), Matsuda et al.
patent: 0 035 384 (1981-09-01), None
patent: WO 93/09788 (1993-05-01), None
patent: WO 93/22431 (1993-11-01), None
patent: WO 95/01773 (1995-01-01), None
patent: WO 95/07362 (1995-03-01), None
patent: WO 95/09175 (1995-04-01), None
patent: WO 96/23508 (1996-08-01), None
patent: WO 97/08314 (1996-08-01), None
patent: WO 96/40989 (1996-12-01), None
patent: WO 97/44450 (1997-11-01), None
patent: WO 98/36066 (1998-12-01), None
patent: WO 99 03507 (1999-01-01), None
patent: WO 01/18015 (2001-03-01), None
U.S. Appl. No. 10/122,630.
U.S. Appl. No. 09/540,843.
Akiyama, M., et al., “Cytostatic Concentrations of Anticancer Agents do not Affect Telomerase Activity of Leukaemic Cells In Vitro”,Eur. J. Cancer, 35 (2):309-315 (1999).
Balasubramanian, S. et al., “Activation of telomerase and its association with G1-phase of the cell cycle during UVB-induced skin tumorigenesis in SKH-1 hairless mouse,”Oncogene, 18:1297-1302 (1999).
Beltz, L. et al., “The Effects of Telomerase Inhibitors on Lymphocyte Function,”,Anticancer Research, 19:3205-3212 (1999).
Cruz, P.D., Jr., et al, “Thymidine Dinucleotides Inhibit Contact Hypersensitivity and Activate the Gene for Tumor Necrosis Factor α,”J. Investigative Dermatology, 114:253-258 (2000).
de Vries, T. J., et al, “Expression of gp100, MART-1, Tyrosinase and S100 in Paraffin-Embedded Primary Melanomas and Locoregional, Lymph Node, and Visceral Metastases: Implications for Diagnosis and Immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group,”J. Pathology, 193:13-20 (2001).
El-Deiry, W.S., et al., “WAF1, a Potential Mediator of p53 Tumor Suppression,”,Cell, 75:817-825 (1993).
Eller, M. S., et al., “The Effects of Oligonucleotide Size and 5001′ Phosphate on Stimulation of Melanogenesis”,Journal of Investigative Dermatology, Abstract No. 113, vol. 112, No. 4, p. 542 (1999).
Eller, M.S., et al., “Enhancement of DNA Repair in Human Skin Cells by Thymidine Dinucleotides: Evidence for a p53-Mediated Mammalian SOS Response”, Proc. Natl. Acad. Sci. USA, 94:12627-12632 (1997).
Fritsche, M. et al., “Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents,”Oncogene8:307-318 (1993).
Hadshiew, I.M., et al., “Stimulation of Melanogenesis by DNA Oligonucleotides: Effect of Size, Sequences and 5′ Phosphorylation,”Journal of Dermatological Science, 127-138 (2001).
Harley, C. B., et al., “Telomerase, Checkpoints and Cancer,” In Cancer Surveys—Advances and Prospects in Clinical, Epidemiological and Laboratory Oncology, Cold Spring Harbor Laboratory Press, 29:263-284 (1997).
Hupp, T. R., et al., “Small Peptides Activate the Latent Sequence-Specific DNA Binding Function of p53,”,Cell, 83:237-245 (1995).
Jayaraman, L. et al., “Activation of p53 Sequence-Specific DNA Binding by Short Single Strands of DNA Requires the p53 C-terminus,”Cell, 81:1021-1029 (1995).
Kastan, M. B., et al., “A Mammalian Cell Cycle Checkpoint Pathway Utilizing p53 and GADD45 Is Defective in Ataxia-Telangiectasia,”Cell, 71:587-597 (1992).
Kern, S. E., et al., “Oncogenic Forms of p53 Inhibit p53-Regulated Gene Expression”,Science, 256:827-830 (1992).
Lu, X. et al., “Differential Induction of Transcriptional Active p53 Following UV or Ionizing Radiation: Defects in Chromosome Instability Syndromes?”,Cell, 75:765-778 (1993).
Mata, J., et al., “A Hexameric Phosphorothioate Oligonucleotide Telomerase Inhibitor Arrests Growth of Burkitt's Lymphoma Cellsin Vitroandin Vivo,” Toxicol. Appl. Pharmacol., 144:189-197 (1997).
Mitchell, D. L., et al., “The Induction and Repair of DNA Photodamage in the Environment”,In Environment UV Photobiology, A.R. Young et al., eds. (NY:Plenum Press), pp. 345-377 (1993).
Mitsudomi, T., et al., “p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence ofrasmutations and clinical features,”,Oncogene7:171-180 (1992).
Nelson, W. G., et al., “DNA Strand Breaks: the DNA Template Alterations That Trigger p53-Dependent DNA Damage Response Pathways,”Mol. and Cell Biol, 14(3):1815-1823 (1994).
Nicolaus, B. J. R., “Symbiotic Approach to Drug Design”,Decision Making in Drug Research, 173-186 (1983).
Niggli, H. J., et al., “Sunlight-Induced Pyrimidine Dimers in Human Skin Fibroblasts in Comparison with Dimerization After Artificial UV-Irradiation,”Photochemistry and Photobiology, 48(3):353-356 (1988).
Norton, J. C. et al., “Inhibition of Human Telomerase Activity by Peptide Nucleic Acids,”Nature Biotechnology, 14:615-619 (1996).
Ohnuma, T., et al., “Inhibitory Effects of Telomere-Mimic Phosphorothiote Oligonucleotides on Various Human Tumor Cellsin Vitro,”, Anticancer Research, 17:2455-2458 (1997).
Page, T. J., et al., “The Cytotoxic Effects of Single-Stranded Telomere Mimics on 0MA-BL1 Cells,”Experimental Cell Research, 252:41-49 (1999).
Parris, C. N., et al., “Telomerase activity in melanoma and non-melanoma skin cancer”,British J. of Cancer, 79 (1):47-53 (1999).
Pedeux, R., et al., “Thymidine Dinucleotides Induce S Phase Cell Cycle Arrest in Addition to Increased Melanogenesis in Human Melanocytes”,J. of Investigative Dermatology, 111:472-477 (1998).
Saeki, T., et al., “Inhibitory Effect of Telomere-Mimic Phosphorothioate Oligodeoxy Nucleotides (S-ODNS) in Human Tumor Cell Lines,”Onocology, 57:27-36 (1999).
Sanchez, Y., et al., “Regulation of RAD53 by the ATM-Like Kinases MEC1 and TEL1 in Yeast Cell Cycle Checkpoint Pathways,”Science, 271:357-360 (1996).
Saretzki, G., et al., “Telomere Shortening Triggers a p53-Dependent Cell Cycle Arrest Via Accumulation of G-Rich Single Stranded DNA Fragments,”Oncogene, 18:5148-5158 (1999).
Walworth, N.C., et al., “rad-Dependent Response of the chk1-Encoded Protein Kinase at the DNA Damage Checkpoint,”Science, 271:353-356 (1996).
Wei, Q., et al., “DNA repair and aging in basal cell carcinoma

Affiliated with

Also associated with

Rating

Method to inhibit cell growth using oligonucleotides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method to inhibit cell growth using oligonucleotides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method to inhibit cell growth using oligonucleotides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3548544